Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the ...

The trial subjects were adults with either type 1 or type 2 diabetes, exhibiting central involvement in diabetic macular ...

In ANI's New Day trial, patients were randomized to an induction phase to receive either a single Iluvien injection or a series of five monthly injections of aflibercept, followed by supplemental ...

ANI Pharmaceuticals (ANIP) stock drops as its Iluvien implant fails in a clinical trial versus Eylea marketed by Regeneron ...

* Alimera Sciences Inc - ‍at 24 months, 86.7 pct of patients maintained or gained vision after receiving iluvien in routine clinical practice Source text for Eikon: Further company coverage ...

Correction to: Eye (2016) 30, 763–764; doi: 10.1038/eye.2015.281; published online 22 January 2016 Since the online publication of this article, it has been noted that the conflict of interest ...

--Alimera Sciences, Inc., a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that INFARMED, the ...

ATLANTA, June 20, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the ...

Iluvien was approved by the Food and Drug Administration back in 2014 for the treatment of DME in patients who were previously treated with corticosteroids without a clinically significant rise in ...

* Alimera Sciences Inc - ‍Under agreement, Horus will serve as Alimera's exclusive distributor in France for Iluvien * Alimera Sciences - ‍Alimera Sciences Limited, Co's European subsidiary ...